Government Partners

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.

Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.

XLV’s solution has the potential to provide image quality that equals or surpasses that which is currently in use, making images easy to analyze, manipulate and transfer much like digital photographs. It will also substantially decrease the cost of digital mammography machines.

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

TORONTO, Feb. 19, 2013 — Xagenic Inc., a privately-held molecular diagnostics company, today announced that it will receive up to $990,000 in funding from the Government of Canada to support design and development of the first lab-free molecular diagnostic platform with a 20-minute time to result.

The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), made the announcement in the keynote speech at the Conference Board of Canada’s Business Innovation Summit 2013 in Toronto this morning.

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

February 6, 2013
Susanne Staer
Awards

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions

TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?

MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for its 16 member institutions.

This announcement was covered by TechVibes, Yonge Street Media and CanTech Letter.

The Networks of Centres of Excellence (NCE) has recognized the increasing strength of this novel partnership by awarding MI $14.95 million in funding through the Centres of Excellence for Commercialization and Research (CECR) program.

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

TORONTO, ON (Jan. 24, 2013) – ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence.

This story was covered in Yonge Street Media on January 30, 2013.

ScarX, a topical medication, emerged from Dr. Benjamin Alman‘s research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation.

Benjamin Alman, founder of ScarX Therapeutics. — **Dr. Benjamin Alman**, founder of ScarX Therapeutics. Photo courtesy of The Hospital for Sick Children.

Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription therapeutic exists to reduce post-surgical scarring. Given this critical need for its technology, ScarX Therapeutics believes sales of the ScarX product could potentially reach into the billions of dollars.

“ScarX is a true game-changer when it comes to reducing the scarring associated with many surgeries,” said Dr. Tom Corr, president and CEO of Ontario Centres of Excellence. “Through our Market Readiness program, OCE is pleased to be supporting both the commercialization of this revolutionary research-based product and Ontario’s economy.”

Flybits featured as Canadian tech export in UKTI Youtube video

June 26, 2012
Susanne Staer
Flybits

U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain.

Flybits, a Mars Innovation spin-off company, was among three companies to be profiled:

http://www.youtube.com/watch?v=9VrtJuSkYqY

Flybits is launching a corporate presence in East London’s Tech City, which is also known as the Silicon Roundabout.

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

At the 2012 BIO International Convention in Boston this week, MaRS Innovation, The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute and the Ontario Centres of Excellence announced we are launching a new life sciences funding program within the Ontario-Québec Corridor.

The Ontario-Québec Life Sciences Corridor was itself announced at the 2011 BIO International Convention. Shortly thereafter, Max Felhmann, president and CEO of CQDM, and Raphael Hofstein, president and CEO of MaRS Innovation, decided to collaborate on a joint pilot project, which has produced Encycle Therapeutics.

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor

Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.

The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto.

Xagenic secures $1 million investment from Ministry of Research & Innovation

Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in…

$15M Funding announcement for CCRM

As part of MaRS Innovation’s strategy to bundle technologies, our first initiative focused on regenerative medicine and creating the Centre for Commercialization of Regenerative Medicine (CCRM) located in Toronto, Ontario.

We are pleased that these efforts have been recognized by the Government of Canada‘s National Centres of Excellence (NCE) program, which recently announced a $15 million funding grant for CCRM through the Centres of Excellence for Commercialization and Research.

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

MaRS Innovation, HTX, OICR and CCR commit over $1 million to speed commercialization of a new rapid molecular diagnostic technology.

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

Flybits featured as Canadian tech export in UKTI Youtube video

Raphael Hofstein’s guest blog for the Ontario Ministry of Economic Development and Innovation

Encycle investigators receive CQDM investment

Xagenic secures $1 million investment from Ministry of Research & Innovation

$15M Funding announcement for CCRM

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

Quick Links

Contact Us